



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#54317

**Date:** March 15, 2024

**Subject:** Graphite Bio, Inc. - Anticipated Cash Distribution  
Option Symbol: GRPH  
New Option Symbol: GRPH1  
Date: ???

Graphite Bio, Inc. (GRPH) has announced a Special Cash Dividend of approximately \$1.03 per GRPH Common Share. The Special Cash Dividend is to be paid to GRPH shareholders in connection with the merger with Lenz Therapeutics, Inc. ("Lenz"). The record date is March 18, 2024; payable date is March 21, 2024. The ex-distribution date for this distribution is to be determined.

At the effective time of the merger with Lenz, Graphite Bio, Inc. (GRPH) is anticipated to undergo a reverse stock split at a ratio that is to be determined and a name/symbol change to Lenz Therapeutics, Inc. (LENZ). The effective time of the merger and reverse split is to be determined.

**Options Contract Adjustment**

**Effective Date:** ???

**New Multiplier:** 100 (e.g., for premium extensions a premium of 1.50 equals \$150; a strike of 5 yields \$500.00).

**Contract Multiplier:** 1

**Strike Prices:** No Change

**Option Symbol:** GRPH changes to GRPH1

**Deliverable Per Contract:**  
1) 100 Graphite Bio, Inc. (GRPH) Common Shares  
2) Approximately \$103.00 Cash (approximately \$1.03 x 100)

**CUSIP:** 38870X104

**Pricing**

Until the final net cash dividend amount is determined, the underlying price for GRPH1 will be determined as follows:

$$\text{GRPH1} = \text{GRPH} + 1.03$$

### **Delayed Settlement**

The GRPH component of the GRPH1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the GRPH1 deliverable until exact cash amount is determined. Upon determination of the exact cash amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).